Abpro Holdings ABPO
OTC ABPO
$0.19 -0.02 (-11.26%)
As of: Aug 21, 2026 · 3:37 PM EDT

Abpro Holdings (ABPO) Cash from Financing Activities (2022 - 2026)

Abpro Holdings' (ABPO) quarterly Cash from Financing Activities came in at $7.4 million in Q1 2026, up 8922.62% YoY from $82138.0 in Q1 2025, and up 1964.35% on a QoQ basis from $359000.0 in Q4 2025.

Abpro Holdings (ABPO) Cash from Financing Activities (2022 - 2026) Analysis & Trends

Abpro Holdings (ABPO) has 5 years of Cash from Financing Activities data on file, last reported at $7.4 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 8922.62% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 20.99% YoY) and the FY2025 annual result came in at $3.1 million, down 72.49% from the prior year.
  • Cash from Financing Activities advanced to $7.4 million in Q1 2026, from $359000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $307.3 million in Q1 2022 to a low of -$276.5 million in Q2 2023.
  • A 5-year average of $25.4 million and a median of $1.2 million in 2024 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 103.58% — and 2026, when it jumped 8922.62%.
  • Tracing ABPO's Cash from Financing Activities over 5 years: stood at -$12000.0 in 2022, then surged by 2311687.17% to $277.4 million in 2023, then tumbled by 97.6% to $6.7 million in 2024, then sank by 94.61% to $359000.0 in 2025, then surged by 1964.35% to $7.4 million in 2026.
  • The last three Cash from Financing Activities figures came in at $7.4 million (Q1 2026), $359000.0 (Q4 2025), and $569000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Abpro Holdings 1.14 Mn 1.14 Mn - -123,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 7.41 Mn
Mar 31, 2026 7.41 Mn
Dec 31, 2025 359,000.00
Dec 31, 2025 359,000.00
Sep 30, 2025 569,000.00
Sep 30, 2025 569,000.00
Jun 30, 2025 2.23 Mn
Jun 30, 2025 2.23 Mn
Mar 31, 2025 -84,000.00
Mar 31, 2025 -84,000.00
Dec 31, 2024 6.67 Mn
Dec 31, 2024 6.67 Mn
Sep 30, 2024 936,000.00
Sep 30, 2024 936,000.00
Jun 30, 2024 1.21 Mn
Jun 30, 2024 1.21 Mn
Mar 31, 2024 2.35 Mn
Mar 31, 2024 2.35 Mn
Dec 31, 2023 277.39 Mn
Dec 31, 2023 277.39 Mn